X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/aacr-bring-car-t-solid-tumors-poseida-thinks-we-need-boost-conditioning-therapy
https://www.fiercepharma.com/manufacturing/gileads-kite-wins-fda-nod-new-car-t-manufacturing-process-speed-yescarta-turnaround
https://www.gilead.com/news-and-press/press-room/press-releases/2023/9/kites-car-t-cell-therapy-yescarta-demonstrates-high-response-rate-and-durable-remission-in-alycante-study-as-initial-treatment-for-transplant-inelig
https://www.pharmatimes.com/news/kites_yescarta_and_tecartus_therapies_show_promise_1492822
https://www.fiercepharma.com/pharma/gilead-confident-cancer-sales-car-t-manufacturing-capabilities
https://www.newswire.ca/news-releases/kite-s-yescarta-r-axicabtagene-ciloleucel-first-car-t-cell-therapy-to-receive-health-canada-authorization-for-use-in-second-line-large-b-cell-lymphoma-876026171.html
https://www.fiercepharma.com/pharma/gilead-kites-yescarta-puts-pressure-bms-breyanzi-overall-survival-win-large-b-cell-lymphoma
https://www.fiercepharma.com/pharma/scotus-denies-bms-final-bid-rehear-appeal-against-gilead
https://www.gilead.com/news-and-press/press-room/press-releases/2022/12/yescarta-now-approved-in-japan-for-initial-treatment-of-relapsedrefractory-large-b-cell-lymphoma
https://www.fiercepharma.com/pharma/daiichi-sankyo-walks-back-yescarta-marketing-deal-gilead-kite
https://www.biopharmadive.com/news/gilead-cell-therapy-yescarta-sales-earnings/635244/
https://www.prnewswire.com/news-releases/nda-for-new-second-line-indication-of-car-t-cell-therapy-product-yikaida-axicabtagene-ciloleucel-injection-approved-for-cde-review-301661624.html
https://www.businesswire.com/news/home/20221017005912/en/Kite%E2%80%99s-Yescarta-First-CAR-T-cell-Therapy-to-Receive-European-Marketing-Authorization-for-Use-in-Second-Line-Diffuse-Large-B-cell-Lymphoma-and-High-grade-B-cell-Lymphoma
https://www.fiercepharma.com/pharma/atara-verge-landmark-approval-first-allogenic-t-cell-therapy
https://pharmaphorum.com/news/gilead-sciences-push-into-oncology-is-paying-off-as-veklury-falters/
https://www.fiercepharma.com/marketing/bristol-myers-breyanzi-broader-fda-nod-brings-car-t-showdown-gilead-earlier-lymphoma
https://www.fiercepharma.com/manufacturing/gileads-kite-pharma-adds-400-jobs-assembles-car-t-therapy-manufacturing-troika-fda
https://www.fiercepharma.com/marketing/gileads-kite-flies-higher-yescarta-leads-car-t-therapy-class-earlier-lymphoma-treatment
https://www.biospace.com/article/intellia-kyvernia-sign-exclusive-deal-to-develop-and-commercialize-new-therapy-versus-autoimmune-diseases/
https://www.fiercepharma.com/marketing/gilead-yescarta-1-5-billion-sales-earlier-lymphoma-game-changing-car-t-data-fast
https://www.businesswire.com/news/home/20211211005047/en/Yescarta%C2%AE-CAR-T-Cell-Therapy-Quadruples-Median-Event-Free-Survival-Duration-Over-Standard-of-Care-in-Second-Line-Relapsed-or-Refractory-Large-B-Cell-Lymphoma
https://www.fiercebiotech.com/biotech/intima-bioscience-poaches-ex-ichnos-ceo-gilead-novartis-resume-to-lead-phase-1-2-asset
https://www.livemint.com/companies/news/blackstone-to-invest-up-to-250-million-in-autolus-therapeutics-of-uk-11636374227693.html
https://www.biospace.com/article/crispr-therapeutics-announces-promising-data-for-its-car-t-cancer-therapy/?s=71
https://www.gilead.com/news-and-press/press-room/press-releases/2021/9/kite-submits-supplemental-biologics-license-application-to-us-food-and-drug-administration-for-earlier-use-of-yescarta-in-large-bcell-lymphoma
https://endpts.com/gileads-kite-earns-second-line-win-for-car-t-yescarta-setting-up-a-battle-over-earlier-blood-cancer-patients/
https://www.biospectrumasia.com/news/25/18435/fosun-kite-gains-first-car-t-cell-therapy-approval-in-china.html
https://www.businesswire.com/news/home/20210612005024/en/Longer-term-Data-for-Kite%E2%80%99s-Yescarta%C2%AE-in-Relapsed-or-Refractory-Follicular-Lymphoma-Demonstrate-Substantial-Survival-Improvement-Over-Current-Therapies-in-Comparative-Analysis
https://www.thepharmaletter.com/article/yescarta-provides-sustained-survival-benefit-vs-current-therapies-in-fl
https://www.newswire.ca/news-releases/kite-s-yescarta-r-axicabtagene-ciloleucel-reimbursed-in-alberta-for-the-treatment-of-certain-types-of-aggressive-non-hodgkin-lymphoma-872725592.html
https://www.fiercepharma.com/pharma/gilead-s-yescarta-gets-a-leg-up-novartis-rival-fda-approval-third-line-follicular-lymphoma
https://www.biospace.com/article/releases/kite-s-yescarta-and-174-axicabtagene-ciloleucel-reimbursed-in-ontario-for-the-treatment-of-certain-types-of-aggressive-non-hodgkin-lymphoma/
https://www.fiercepharma.com/pharma/ash-gilead-s-car-t-med-yescarta-shows-promise-earlier-lymphoma-therapy
Market Place
Share 
